Publication | Closed Access

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

InflammationRheumatologyAutoimmune DiseaseFuture 2MedicineImmunologyClinical DermatologyAutoimmunityInflammatory Rheumatic DiseaseDermatologyPsoriatic Arthritis